fashion -WSS

fashion

author：Wikipedia 2025-09-29 01:35:06 - browse：253

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： The (many) problems with a new study criticizing cancer screening

WSS

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Stem cell treatment guidelines are released by FDA

Biogen nominates mother of director’s child to replace him on board

FDA approves first new drug developed for postpartum depression

Bispecific antibodies are next new thing in cancer immunotherapy

focus

fashion

focus

New air purifier tech could be key to improving indoor air quality

What drug price negotiations mean for Medicare Part D

Dobbs anniversary: the lost opportunity of abortion as health care

AstraZeneca chief proposes a novel edit to the drug pricing bill

Peter Hotez and the public health issue of online harassment

The thinking behind the controversial eating disorder chatbot Tessa

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How to fix the rural physician shortage in the U.S.

Drug repurposing or repositioning? The language matters

What drug price negotiations mean for Medicare Part D

hotspot

Illumina names Agilent executive as new CEO

Altering the blood type of lungs raises potential for universal organs for transplants

FDA approves first new drug developed for postpartum depression

FDA approves first new drug developed for postpartum depression

Timeline: Key moments in fight for gay rights

Sea level rise could wash away turtle breeding grounds around the world, researchers say

leisure time

focus

hotspot

Wikipedia